Selected research
Industry Research
Pet Biopharmaceuticals Industry Research Report 2026
Market perspective
The global Pet Biopharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pet Biopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pet Biopharmaceuticals market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pet Biopharmaceuticals market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pet Biopharmaceuticals include Merck, Zoetis, Virbac, Vetoquinol, Ouro Fino Saude, Norbrook, Jindun, Elanco and Dechra Veterinary Products, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pet Biopharmaceuticals market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pet Biopharmaceuticals.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pet Biopharmaceuticals Market by Company
Merck
Zoetis
Virbac
Vetoquinol
Ouro Fino Saude
Norbrook
Jindun
Elanco
Dechra Veterinary Products
Chopperlvya Animal Health
Ceva
CAHIC
Boehringer Ingelheim
Pet Biopharmaceuticals Segment by Type
Antiparasitic
Antibacterial
Biological Products
Others
Pet Biopharmaceuticals Segment by Application
Prevention
Treatment
Pet Biopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pet Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Biopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pet Biopharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antiparasitic
- Antibacterial
- Biological Products
- Others
Applications
- Prevention
- Treatment
Companies covered
- Merck
- Zoetis
- Virbac
- Vetoquinol
- Ouro Fino Saude
- Norbrook
- Jindun
- Elanco
- Dechra Veterinary Products
- Chopperlvya Animal Health
- Ceva
- CAHIC
- Boehringer Ingelheim
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pet Biopharmaceuticals by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Antiparasitic
- 2.2.3 Antibacterial
- 2.2.4 Biological Products
- 2.2.5 Others
- 2.3 Pet Biopharmaceuticals by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Prevention
- 2.3.3 Treatment
- 2.4 Assumptions and Limitations
3 Pet Biopharmaceuticals Breakdown Data by Type
- 3.1 Global Pet Biopharmaceuticals Historic Market Size by Type (2021-2026)
- 3.2 Global Pet Biopharmaceuticals Forecasted Market Size by Type (2027-2032)
4 Pet Biopharmaceuticals Breakdown Data by Application
- 4.1 Global Pet Biopharmaceuticals Historic Market Size by Application (2021-2026)
- 4.2 Global Pet Biopharmaceuticals Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pet Biopharmaceuticals Market Perspective (2021-2032)
- 5.2 Global Pet Biopharmaceuticals Growth Trends by Region
- 5.2.1 Global Pet Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pet Biopharmaceuticals Historic Market Size by Region (2021-2026)
- 5.2.3 Pet Biopharmaceuticals Forecasted Market Size by Region (2027-2032)
- 5.3 Pet Biopharmaceuticals Market Dynamics
- 5.3.1 Pet Biopharmaceuticals Industry Trends
- 5.3.2 Pet Biopharmaceuticals Market Drivers
- 5.3.3 Pet Biopharmaceuticals Market Challenges
- 5.3.4 Pet Biopharmaceuticals Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pet Biopharmaceuticals Players by Revenue
- 6.1.1 Global Top Pet Biopharmaceuticals Players by Revenue (2021-2026)
- 6.1.2 Global Pet Biopharmaceuticals Revenue Market Share by Players (2021-2026)
- 6.2 Global Pet Biopharmaceuticals Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pet Biopharmaceuticals Head Office and Area Served
- 6.4 Global Pet Biopharmaceuticals Players, Product Type & Application
- 6.5 Global Pet Biopharmaceuticals Manufacturers Established Date
- 6.6 Global Pet Biopharmaceuticals Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pet Biopharmaceuticals Market Size (2021-2032)
- 7.2 North America Pet Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 7.4 North America Pet Biopharmaceuticals Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pet Biopharmaceuticals Market Size (2021-2032)
- 8.2 Europe Pet Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 8.4 Europe Pet Biopharmaceuticals Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pet Biopharmaceuticals Market Size (2021-2032)
- 9.2 Asia-Pacific Pet Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pet Biopharmaceuticals Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pet Biopharmaceuticals Market Size (2021-2032)
- 10.2 South America Pet Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 10.4 South America Pet Biopharmaceuticals Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pet Biopharmaceuticals Market Size (2021-2032)
- 11.2 Middle East & Africa Pet Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pet Biopharmaceuticals Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck
- 12.1.1 Merck Company Information
- 12.1.2 Merck Business Overview
- 12.1.3 Merck Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.1.4 Merck Pet Biopharmaceuticals Product Portfolio
- 12.1.5 Merck Recent Developments
- 12.2 Zoetis
- 12.2.1 Zoetis Company Information
- 12.2.2 Zoetis Business Overview
- 12.2.3 Zoetis Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.2.4 Zoetis Pet Biopharmaceuticals Product Portfolio
- 12.2.5 Zoetis Recent Developments
- 12.3 Virbac
- 12.3.1 Virbac Company Information
- 12.3.2 Virbac Business Overview
- 12.3.3 Virbac Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.3.4 Virbac Pet Biopharmaceuticals Product Portfolio
- 12.3.5 Virbac Recent Developments
- 12.4 Vetoquinol
- 12.4.1 Vetoquinol Company Information
- 12.4.2 Vetoquinol Business Overview
- 12.4.3 Vetoquinol Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.4.4 Vetoquinol Pet Biopharmaceuticals Product Portfolio
- 12.4.5 Vetoquinol Recent Developments
- 12.5 Ouro Fino Saude
- 12.5.1 Ouro Fino Saude Company Information
- 12.5.2 Ouro Fino Saude Business Overview
- 12.5.3 Ouro Fino Saude Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.5.4 Ouro Fino Saude Pet Biopharmaceuticals Product Portfolio
- 12.5.5 Ouro Fino Saude Recent Developments
- 12.6 Norbrook
- 12.6.1 Norbrook Company Information
- 12.6.2 Norbrook Business Overview
- 12.6.3 Norbrook Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.6.4 Norbrook Pet Biopharmaceuticals Product Portfolio
- 12.6.5 Norbrook Recent Developments
- 12.7 Jindun
- 12.7.1 Jindun Company Information
- 12.7.2 Jindun Business Overview
- 12.7.3 Jindun Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.7.4 Jindun Pet Biopharmaceuticals Product Portfolio
- 12.7.5 Jindun Recent Developments
- 12.8 Elanco
- 12.8.1 Elanco Company Information
- 12.8.2 Elanco Business Overview
- 12.8.3 Elanco Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.8.4 Elanco Pet Biopharmaceuticals Product Portfolio
- 12.8.5 Elanco Recent Developments
- 12.9 Dechra Veterinary Products
- 12.9.1 Dechra Veterinary Products Company Information
- 12.9.2 Dechra Veterinary Products Business Overview
- 12.9.3 Dechra Veterinary Products Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.9.4 Dechra Veterinary Products Pet Biopharmaceuticals Product Portfolio
- 12.9.5 Dechra Veterinary Products Recent Developments
- 12.10 Chopperlvya Animal Health
- 12.10.1 Chopperlvya Animal Health Company Information
- 12.10.2 Chopperlvya Animal Health Business Overview
- 12.10.3 Chopperlvya Animal Health Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.10.4 Chopperlvya Animal Health Pet Biopharmaceuticals Product Portfolio
- 12.10.5 Chopperlvya Animal Health Recent Developments
- 12.11 Ceva
- 12.11.1 Ceva Company Information
- 12.11.2 Ceva Business Overview
- 12.11.3 Ceva Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.11.4 Ceva Pet Biopharmaceuticals Product Portfolio
- 12.11.5 Ceva Recent Developments
- 12.12 CAHIC
- 12.12.1 CAHIC Company Information
- 12.12.2 CAHIC Business Overview
- 12.12.3 CAHIC Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.12.4 CAHIC Pet Biopharmaceuticals Product Portfolio
- 12.12.5 CAHIC Recent Developments
- 12.13 Boehringer Ingelheim
- 12.13.1 Boehringer Ingelheim Company Information
- 12.13.2 Boehringer Ingelheim Business Overview
- 12.13.3 Boehringer Ingelheim Revenue in Pet Biopharmaceuticals Business (2021-2026)
- 12.13.4 Boehringer Ingelheim Pet Biopharmaceuticals Product Portfolio
- 12.13.5 Boehringer Ingelheim Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst